Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Scientists at Invictus Oncology Design Targeted Therapy for Cancer Treatment

By Invictus Oncology Private Limited | March 13, 2017

(Credit: Associated Press)

Scientists at Invictus Oncology Pvt. Ltd. have utilized a novel linker chemistry to generate antibody-drug conjugates which act like “magic bullets,” a concept proposed by Nobel laureate, Paul Ehrlich. The technology can provide a targeted therapy to cancer patients whereby the antibody can home into specific markers or “addresses” expressed by cancer cells to deliver extremely toxic drugs.

The major challenge in the field has been to define an optimal linker chemistry that prevents the drug from breaking off from the antibody in the bloodstream but releases the drug once it reaches the tumor.

The linker chemistry developed by Invictus team enables the combination of biologically active anti-cancer drugs and tumor-targeting antibodies, providing a sensitive distinction between normal and tumor cells. Utilizing the novel technology, the therapy minimizes side effects and maximizes antitumor efficacy.

The lead author of the paper, which was published in the March 2017 issue of Chemical Science (Chem. Sci., 2017, 8, 2387-2395), is Nimish Gupta, Scientist II at Invictus Oncology. The paper’s senior authors are Monideepa Roy, Director-R&D, Invictus Oncology and Shiladitya Sengupta, Faculty Member at Harvard Medical School and Co-founder of Invictus. 

Invictus Oncology is a biopharmaceutical company based in Delhi, India focused on the development of novel therapeutics for cancer treatment. It was co-founded by Harvard Medical School’s Dr. Shiladitya Sengupta and Padma Vibhushan Dr. Raghunath A. Mashelkar.

(Source: PR Newswire)


Filed Under: Drug Discovery

 

Related Articles Read More >

EpicentRx
A next-gen vaccine that could help end COVID-19 whack-a-moleĀ 
Dotmatics
How Dotmatics aims to help reduce the drug discovery failure rate
Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50